How effective is Vebreltinib in treating glioma?

Vebreltinib has demonstrated unique targeting advantages in the treatment of glioma. Glioma is a type of highly aggressive central nervous system tumor. Traditional treatments include surgery, radiotherapy and chemotherapy, but the patient's recurrence rate is high and the prognosis is poor. By inhibiting c-Met receptor and PTPRZ1-MET fusion gene-related signals, boricitinib can interfere with the growth and migration of tumor cells and promote apoptosis of cancer cells, thus delaying disease progression to a certain extent.

Currently, bricitinib has been approved in China for usePatients with PTPRZ1-MET fusion gene-positive brain glioma and astrocytoma. Clinical data show that patients treated with bricitinib can observe stable or partial reduction in tumor volume on imaging, and improvements in symptoms such as headache, nausea, and impaired cognitive function. Its oral administration form facilitates long-term maintenance treatment, reduces damage to normal brain tissue, and improves patients' quality of life.

The advantages of bricitinib compared with traditional chemotherapy include high targeting and lower systemic toxic and side effects. Its mechanism selectively inhibits cancer cells and has less impact on healthy cells, thereby reducing treatment-related discomfort. Some clinical trials are exploring the possibility of combining bricitinib with other targeted drugs or immunotherapies to improve efficacy and extend progression-free survival. Nevertheless, the efficacy is still affected by tumor type, patient age, genetic mutation type and previous treatment, so its treatment plan is crucial.

It should be noted that drug resistance may occur with long-term use of targeted drugs, and some patients may experience disease progression after a period of treatment. Therefore, regular imaging evaluation and symptom monitoring are important measures to ensure therapeutic efficacy. At the same time, clinicians will adjust the dose or explore combination therapies based on patient tolerance to extend the duration of efficacy.

Reference materials:https://www.asymbio.com.cn/